Nucleic Acid Aptamers: Research Tools in Disease Diagnostics and Therapeutics

Table 2

A list of aptamers in clinical pipeline.

Name of aptamer	Company	Target	Indication	Current phase	References
Macugen	Pfizer/Eyetech	VEGF	AMD	Approved	[29, 80]
AS1411	Antisoma	Nucleolin	AML	Phase II	[81]
REG1	Regado	Coagulation factor IXa	ACS	Phase III	[82]
ARC1779	Archemix	vWF	TTP	Phase II	[83]
NU172	ARCA	Thrombin	CABG	Phase II	[84, 85]
E10030	Ophthotech	PDGF	AMD	Phase II	[86]
ARC1905	Ophthotech	C5	AMD	Phase I	[84, 85]
NOX-E36	NOXXON	MCP-1; (CCL2)	Type2DN	Phase II	[87]
NOX-A12	NOXXON	SDF-1; (CXCL12)	Cancer	Phase I	[87]
NOX-H94	NOXXON	Hepcidin	Anemia	Phase I	[88]
BAX499 or; ARC19499	Baxter/Archemix	TFPI	Hemophilia	Phase I	[84, 89]

AMD: age-related macular degeneration, AML: acute myeloid leukemia, ACS: acute coronary syndrome, vWF: A1 domain of von willebrand factor, TTP: thrombotic thrombocytopenic purpurea, CABG: coronary artery bypass grafting, DN: diabetic nephropathy, CCL2: chemokine (C-C motif) ligand 2, also known as MCP1, CXCL12: chemokine (C-X-C motif) ligand 12, also known as SDF-1𝛼, and TFP1: tissue factor pathway inhibitor.